Switch to
More onapp

Balaxi Pharmaceuticals Ltd

BALAXI
Health CareHealth Care Equipment & Supplies
SmallcapWith a market cap of ₹571 cr, stock is ranked 1,278
High RiskStock is 3.03x as volatile as Nifty
584.104.90 (-0.83%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareHealth Care Equipment & Supplies
SmallcapWith a market cap of ₹571 cr, stock is ranked 1,278
High RiskStock is 3.03x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
11.99
PB RatioPB Ratio
5.05
Dividend YieldDiv. Yield
0.09%
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Balaxi Pharmaceuticals Limited is an India-based pharmaceutical company engaged in the business of International Wholesale distribution of Pharmaceuticals, Builders Hardware and Fast-moving consumer goods (FMCG). The Company’s products include Nice 45 G, Guloso 45 G, Snax! 42 G, Doce E Sal 42 G, Yumm 75 G and Boadent. The Company is offerings more than 300 products across multiple therapeutic areas, including Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steriod, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhoea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative.

Investor PresentationView older 

Nov 5, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

201920202021202214.4946.22233.56284.361.986.0938.1347.66
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 17, 2022

BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about related party transaction for the period ended September 2022 | Download

BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about related party transaction for the period ended September 2022 | Download

Transcript of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 15, 2022

BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call | Download

BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call | Download

Cash Dividend 
Ex. DateJul 1, 2022

Final • Div/Share: ₹ 0.5

See all events